Items Tagged ‘Rectal Cancer’

July 28th, 2016

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers

By

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These results were recently published in the Journal of the National Cancer Institute. Among patients with colorectal cancer that has spread to […]

View full entry

Tags: 5fu, Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, colorectal cancer, crc, dmmr, eloxatin, mismatch repair, News, oxaliplatin, Rectal Cancer, Stages I-III Rectal Cancer


May 11th, 2016

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer

By

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently published in The Lancet Oncology. The HER2 receptor is a protein that is normally found on the surface of several different types of cells […]

View full entry

Tags: Colon Cancer, colorectal cancer, HER2-positive, herceptin, lapatinib, News, Rectal Cancer, trastuzumab, Tykerb


May 9th, 2016

Another Study Confirms That Daily Aspirin Lowers Risk of Colorectal & Other GI Tract Cancers

By

The regular use of aspirin significantly reduces the overall risk of cancer, especially colorectal and other gastrointestinal tract cancers, according to a study published in JAMA Oncology.1 The recent report supports the results of previous clinical studies that have also demonstrated that the daily use of aspirin reduces the risk of death from several common cancers, including lung, […]

View full entry

Tags: aspirin, benefit, cancer, Colon Cancer, colorectal, daily, Esophageal Cancer, gastrointestinal, lung, Lung Cancer, News, Rectal Cancer


May 2nd, 2016

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection

By

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated for individuals at an average risk of developing colorectal cancer who choose not to undergo other colorectal cancer screening methods specified in […]

View full entry

Tags: approval, Colon Cancer, colorectal cancer, EPI proColon, fda, News, non-invasive, Rectal Cancer, risk, screening, Screening/Prevention Colon Cancer, Screening/Prevention Rectal Cancer


March 14th, 2016

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers

By

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly 70 percent, according to the results of a new study. There is a well-documented association between exposure to radiation […]

View full entry

Tags: Bladder Cancer, bowel cancer, carcinogenesis, Colon Cancer, exposure, Hodgkin's Lymphoma, News, Prostate Cancer, radiation therapy, Rectal Cancer, secondary cancer


March 4th, 2016

Anesthesia Increases Colonoscopy Risks

By

Though colonoscopy is often performed with anesthesia, a recent study published in the journal Gastroenterology has found that sedation increases the risk of complications.1 A colonoscopy is a type of exam that a doctor uses to check the lining of the large intestine (colon) for signs of cancer, abnormal areas that could turn into cancer, […]

View full entry

Tags: Anal Cancer, anesthesia, Colon Cancer, colonoscope, colonoscopy, News, Rectal Cancer, risks, Screening/Prevention Anal Cancer, Screening/Prevention Colon Cancer, Screening/Prevention Rectal Cancer


February 11th, 2016

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents

By

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or Xeloda (capecitabine), or who develop certain severe […]

View full entry

Tags: Anal Cancer, Breast Cancer, capecitabine, Colon Cancer, fda, fluorouracil, Gastric Cancer, Gastrointestinal Stromal Tumors, life-threatening, Liver Cancer, News, Pancreatic Cancer


February 3rd, 2016

Colorectal Cancer: Year in Review

By

After several years of exciting developments in colorectal cancer research and therapy, progress continued throughout 2015. The FDA approved a new drug to treat colorectal cancer, and much research has been done with combination therapies and protocols for treatment. Of great importance, research shows that when colorectal cancer is detected during a screening colonoscopy, patients […]

View full entry

Tags: Colon Cancer, News, Rectal Cancer


January 28th, 2016

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing

By

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no RAS mutations, or those with only the KRAS exon 2 mutation. These results were recently presented at the […]

View full entry

Tags: Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, colorectal cancer, KRAS exon 2, News, panitumumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, Stages I-III Rectal Cancer, vectibix


November 16th, 2015

Does Processed Meat Cause Colorectal Cancer?

By

According to the International Agency for Research on Cancer (IARC), eating processed meat products can increase a person’s risk for developing colorectal cancer. Processed meat is classified as meat that has been salted, cured, fermented, or smoked to add flavor or preserve the meat. These meats include ham, bacon, sausages, corned beef, hot dogs, canned […]

View full entry

Tags: Colon Cancer, News, prevention, processed meat, Rectal Cancer, Screening/Prevention Colon Cancer, Screening/Prevention Rectal Cancer


September 30th, 2015

Lonsurf® Approved for the Treatment of Colorectal Cancer

By

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S. although death rates from colorectal cancer have declined in the past 10 years which is thought to be due […]

View full entry

Tags: advanced, Colon Cancer, colorectal cancer, fda, Lonsurf, News, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, tipiracil, trifluridine


August 24th, 2015

XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing

By

XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal cancer. The US based trial is ongoing at multiple sites. Xilonix, a novel anti-cancer agent, is being developed via a ground-breaking regulatory path that XBiotech established […]

View full entry

Tags: advanced colorectal cancer, clinical trail, Colon Cancer, News, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, xilonix


August 11th, 2015

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy

By

  Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers have announced that that drug has extended overall survival, the primary goal of the study. Vectibix is a targeted therapy that […]

View full entry

Tags: Colon Cancer, colorectal cancer, kras, metastatic colorectal cancer, News, panitumumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, vectibix, wild-type


July 21st, 2015

Cancers Caught During Screening Colonoscopy are More Survivable

By

Patients whose colorectal cancer (CRC) is detected during a screening colonoscopy are likely to survive longer than those who wait until they have symptoms before having the test, according to a study in the July issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE). The study, […]

View full entry

Tags: Colon Cancer, colonoscopy, colorectal cancer, News, Rectal Cancer, screening, Screening/Prevention Colon Cancer, Screening/Prevention Rectal Cancer


June 23rd, 2015

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment

By

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal […]

View full entry

Tags: Colon Cancer, colorectal cancer, irinotecan, metastatic, News, oxaliplatin, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer